USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $1.87, $0.16 better than the analyst estimate of $1.71. Revenue for the quarter came in at $336.8 million versus the consensus estimate of $332.61 million.

GUIDANCE:

Reiterates 2021 net sales and diluted EPS outlook.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.